Brendon L. Neuen - Publications

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 04, 2026

ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.

Journal: Journal of the American Society of Nephrology : JASN

Published: September 02, 2026

Does Intravenous Iron Improve Survival and Physical Function and Reduce Heart Failure Events in Patients with Chronic Kidney Disease?

Journal: NEJM evidence

Published: August 25, 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Journal: Nature reviews. Nephrology

Published: August 06, 2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

Journal: European heart journal

Published: July 24, 2026

A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: June 23, 2026

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

Journal: JAMA

Published: June 05, 2026

Finerenone in Persons with Chronic Kidney Disease without Diabetes.

Journal: The New England journal of medicine

Published: June 05, 2026

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.

Journal: Diabetes, obesity & metabolism

Published: May 19, 2026

Cardiologists as Champions of Kidney Health in the CKM Era.

Journal: Journal of the American College of Cardiology

Published: May 07, 2026

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Journal: Lancet (London, England)

Published: April 23, 2026

Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

Journal: British journal of clinical pharmacology

Published: April 17, 2026